Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/23030
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLengyel, E.en
dc.contributor.authorPrechtel, D.en
dc.contributor.authorResau, J. H.en
dc.contributor.authorGauger, K.en
dc.contributor.authorWelk, A.en
dc.contributor.authorLindemann, K.en
dc.contributor.authorSalanti, G.en
dc.contributor.authorRichter, T.en
dc.contributor.authorKnudsen, B.en
dc.contributor.authorVande Woude, G. F.en
dc.contributor.authorHarbeck, N.en
dc.date.accessioned2015-11-24T19:30:09Z-
dc.date.available2015-11-24T19:30:09Z-
dc.identifier.issn0020-7136-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/23030-
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAged, 80 and overen
dc.subjectBreast Neoplasms/drug therapy/*metabolism/*pathologyen
dc.subjectDisease Progressionen
dc.subjectDisease-Free Survivalen
dc.subjectFemaleen
dc.subjectFibrocystic Breast Disease/drug therapy/metabolism/pathologyen
dc.subjectHepatocyte Growth Factor/metabolismen
dc.subjectHumansen
dc.subjectHyperplasia/drug therapy/metabolism/pathologyen
dc.subjectLigandsen
dc.subjectLymph Nodes/pathologyen
dc.subjectLymphatic Metastasis/*pathologyen
dc.subjectMiddle Ageden
dc.subjectNeoplasm Stagingen
dc.subjectPilot Projectsen
dc.subjectProto-Oncogene Proteins c-met/*metabolismen
dc.subjectReceptor, erbB-2/*metabolismen
dc.subjectReceptors, Estrogen/metabolismen
dc.subjectReceptors, Progesterone/metabolismen
dc.subjectRisk Factorsen
dc.subjectSurvival Rateen
dc.subjectTreatment Outcomeen
dc.titleC-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neuen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.primary10.1002/ijc.20598-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/15455388-
heal.identifier.secondaryhttp://onlinelibrary.wiley.com/store/10.1002/ijc.20598/asset/20598_ftp.pdf?v=1&t=h0dok7re&s=254db45fd575faa12905ce0be944e6cd20b0278f-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate2005-
heal.abstractReceptor tyrosine kinases play an important role in malignant transformation of epithelial cells by activating signal transduction pathways important for proliferation, invasion and metastasis. In a pilot study (n = 40), we evaluated expression of the c-Met and Her2/neu receptor tyrosine kinases and the c-Met ligand hepatocyte growth factor/scatter factor (HGF/SF) in primary breast cancers and their lymph node metastases using both conventional immunohistochemistry and confocal immunofluorescence. Neither c-Met and HGF/SF nor Her2/neu expression correlated with established prognostic factors such as age, lymph node involvement, estrogen receptor (ER), progesterone receptor (PR), tumor size, or grade. Both staining methods confirmed a significant correlation between c-Met overexpression and a high risk of disease progression. Furthermore, among tumors with c-Met overexpression, only 50% also overexpress Her2/neu, thus identifying a subset of patients with aggressive disease in addition to Her2/neu. Median disease-free survival in patients with c-Met overexpressing tumors was 8 months compared to 53 months when c-Met expression was low (p = 0.037; RR = 3.0). This significant impact of c-Met on tumor aggressiveness independent of Her2/neu was also confirmed by multivariate analysis. In conclusion, the role of c-Met expression as a prognostic variable and consequently as an interesting target for novel therapeutic approaches deserves further analysis in a larger cohort of patients.en
heal.journalNameInt J Canceren
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Files in This Item:
File Description SizeFormat 
Lengyel-2005-C-Met overexpression.pdf295.88 kBAdobe PDFView/Open    Request a copy


This item is licensed under a Creative Commons License Creative Commons